Drug Trial Radar · NCT05704036
Estrogen Supplementation and Bone Health in Women With CF
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
May 2, 2023
Primary completion
Jan 2028
Study completion Jan 2029
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cystic Fibrosis Foundation
- First posted
- Jan 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 0 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to learn about the role of estrogen and other hormones in bone development in adolescent and young adult women with cystic fibrosis (CF). The study has two main components, an observational study and a feasibility sub-study. The main questions it aims to answer are: * How do different forms of hormonal contraception (e.g. birth control pill or other progesterone only methods) impact bone health? * Is a study of transdermal estradiol (estrogen skin patches) feasible in this group? * How does transdermal estradiol impact bone health and quality of life? Participants in the observational study will have three study visits (baseline, 6 months, and 12 months). At all visits, participants will have blood drawn and will complete questionnaires. At the baseline and 12 month visits, participants will additionally have x-rays and DXAs (bone density assessment). Between visits, participants will complete brief questionnaires. Researchers will compare various measurements over time to assess the impact of different forms of hormonal contraception. Participants in the feasibility sub-study will apply transdermal estradiol patches once weekly for 12 months, fill out brief quality-of-life surveys in between study visits, and complete blood draws and questionnaires at four study visits (baseline, 3 months, 6 months, and 12 months). The participants will also have x-rays and DXAs performed at the baseline and 12 month visits. Researchers will examine changes in various measurements to determine the impact of transdermal estradiol.
Conditions
- Cystic Fibrosis
- Hypoestrogenism
Interventions
Transdermal estrogenDrug
Transdermal estradiol 0.1 mg/day, applied once weekly
ProgesteroneDrug
Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in lumbar spine bone mineral density assessed by dual-energy x-ray absorptiometry (DXA)Time frame: Baseline and 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Johns Hopkins
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.